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Abstract
Introduction No study has investigated how exercise modifies the effect of fall-related drugs (FRDs) on falls among people 
with Alzheimer’s disease (AD).
Objective The aim of this study was to investigate how exercise intervention and FRDs interact with fall risk among patients 
with AD.
Methods In the FINALEX trial, community-dwelling persons with AD received either home-based or group-based exercise 
twice weekly for 1 year (n =129); the control group received normal care (n =65). The number of falls was based on spouses’ 
fall diaries. We examined the incidence rate ratios (IRRs) for falls among both non-users and users of various FRDs (antihy-
pertensives, psychotropics, drugs with anticholinergic properties [DAPs]) in both control and combined intervention groups.
Results Between the intervention and control groups, there was no difference in the number of falls among those without 
antihypertensives or psychotropics. In the intervention group taking antihypertensives, the IRR was 0.5 falls/person-year (95% 
confidence interval [CI] 0.4–0.6), while in the control group, the IRR was 1.5 falls/person-year (95% CI 1.2–1.8) [p < 0.001 
for group, p = 0.067 for medication, p < 0.001 for interaction]. Among patients using psychotropics, the intervention group 
had an IRR of 0.7 falls/person-year (95% CI 0.6–0.9), while the control group had an IRR of 2.0 falls/person-year (95% CI 
1.6–2.5) [p < 0.001 for group, p = 0.071 for medication, p < 0.001 for interaction]. There was a significant difference in 
falls between the intervention and control groups not using DAPs (0.6, 95% CI 0.5–0.7; 1.2, 95% CI 1.0–1.4), and between 
the intervention and control groups using DAPs (1.1, 95% CI 0.8–1.3; 1.5, 95% CI 1.0–2.1) [p < 0.001 for group, p = 0.014 
for medication, p  = 0.97 for interaction].
Conclusion Exercise has the potential to decrease the risk for falls among people with AD using antihypertensives and 
psychotropics.
Trial Registration ACTRN12608000037303.
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Key Points 
Exercise has the potential to reduce the fall risk related 
to antihypertensives and psychotropics among people 
with Alzheimer’s disease (AD).
Exercise decreased the risk for falls regardless of polyp-
harmacy among people with AD.
Drugs with anticholinergic properties (DAPs) increased 
the risk for falls; however, exercise reduced the risk 
among both non-users and users of DAPs among people 
with AD.
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1 Introduction
Polypharmacy and several drug classes expose older peo-
ple to the risk of falls [1]. The use of psychotropics is 
associated with falls among older people [2, 3], especially 
among nursing-home residents [4]. Furthermore, drugs 
with anticholinergic properties (DAPs) are associated with 
an increased frequency of falls [5, 6], while antihyperten-
sives are associated with an increased risk for falls [2, 3] 
and hip fractures [7].
Approximately 60% of older persons with dementia or 
cognitive impairment fall annually [8, 9]. Several possible 
fall risk factors such as advanced age, female sex, history 
of falls, symptomatic orthostatic hypotension, disability, 
frailty, advanced dementia and comorbidities [10–18], as 
well as protective factors such as physical activity and 
better physical functioning [12, 18], have been suggested 
to be associated with falls among people with dementia. 
However, to our knowledge, fall-related drugs (FRDs) 
other than psychotropics have not been studied as risk 
factors among people with dementia.
Recent (2015) systematic reviews and meta-analyses 
found that physical exercise may significantly prevent 
falls, even among older persons with cognitive impair-
ment [19] or dementia [20]. It has been suggested that the 
decrease in falls might be due to improvement in muscle 
strength and mobility functioning [15], although the exact 
mechanism remains unclear. Furthermore, no studies have 
examined whether exercise intervention can modify the 
risk of FRDs among persons with dementia.
The aim of this study, which is a secondary analysis of 
FINALEX trial data, was to investigate possible interac-
tions between exercise intervention and FRDs on fall risk 
among patients with Alzheimer’s disease (AD).
2  Methods
The FINALEX study investigated exercise among persons 
with AD [21]. The intervention participants experienced 
benefit with respect to falls [21], and we also found sev-
eral risk and protective factors (including FRDs) for falls 
among patients with AD [18]. In the FINALEX study, 
patients with AD were comprehensively assessed at base-
line for medication use and various other risk factors [21, 
22]. In addition, patients’ spouses kept detailed diaries on 
falls and their characteristics, during the follow-up year.
The original FINALEX study (a randomized controlled 
trial) had both home-based and group-based exercise inter-
vention arms; the control group received normal commu-
nity care [21]. The intervention groups fell significantly 
less during the 12 months of follow-up compared with the 
control group [21]. In this analysis, we merged the home-
based and group-based intervention groups into a single 
intervention group, which we compared with the control 
group with regard to incidence rate ratios (IRRs) of falls, 
various FRDs, and their interaction.
2.1  Participants
In 2008, Alzheimer’s patients living with a spouse in the cit-
ies of Helsinki, Vantaa or Espoo (N = 1264) were recruited 
by the Social Insurance Institution of Finland, based on its 
drug reimbursement register. An interest in participation was 
expressed by 497 persons, 390 of whom were able to be con-
tacted by study nurses. Eighty-four persons did not wish to 
participate and 96 did not fulfil the inclusion criteria, which 
included the following: (1) Finnish-language speaker; (2) 
living with a spouse at home; (3) living in Helsinki, Vantaa 
or Espoo; (4) ≥ 65 years of age and retired; (5) absence of 
severe hemiplegia or diagnosed terminal disease; (6) able 
to walk independently with or without a mobility aid; and 
(7) having at least one sign of possible frailty (one or more 
falls during the previous year, unintentional weight loss, or 
decreased walking speed). A total of 210 patients met our 
inclusion criteria and were included and randomised in the 
study.
The study was approved by the Ethics Committee of 
the Helsinki University Hospital. Informed consent was 
obtained for all patients in the original FINALEX study, 
with spouses providing informed consent when the patients 
had reduced judgment capacity.
2.2  Clinical Measures
Demographic factors including sex, age, education and 
vision problems (reading ability) were recorded at baseline. 
Body mass index (BMI, the person’s weight in kilograms 
divided by their height in meters squared) and blood pres-
sure were also measured at baseline. The Mini Nutritional 
Assessment (MNA) [23] was used to assess the patient’s 
nutritional status. Medical records confirmed medication 
use and comorbidities, after which the Charlson Comorbid-
ity Index [24] was calculated. The Clinical Dementia Rat-
ing (CDR) scale [25] and the Mini-Mental State Examina-
tion (MMSE) [26] were used to evaluate cognitive status, 
whereas the Functional Independence Measure (FIM) [27] 
and Short Physical Performance Battery (SPPB) [28] were 
used to evaluate physical functioning and mobility. The 
SPPB includes tests of balance, walking speed, and ris-
ing from a chair; we administered the balance and walking 
speed tests separately [28]. The number of falls during a 
12-month period was based on the fall diaries kept by the 
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patients’ spouses during the study. At baseline, the spouses 
were asked if the patients had had fall(s) in the previous year.
Polypharmacy was defined as regularly taking nine or 
more systemic medications. In previous publications, poly-
pharmacy has been defined as the use of five or more drugs, 
and excessive polypharmacy has been defined as more 
than nine drugs [29]. We used a cut-point of nine or more 
to increase the statistical power. Medications with World 
Health Organization (WHO) Anatomical Therapeutic Chem-
ical (ATC) classification system codes [30] C03 (diuretics), 
C07 (beta-blocking agents), C08 (calcium channel block-
ers) and C09 (agents acting on the renin-angiotensin system) 
were included in antihypertensives, whereas medications 
with WHO ATC codes N05A (antipsychotics), N05B (anxi-
olytics), N05C (hypnotics and sedatives) and N06A (anti-
depressants) were included in psychotropics. DAPs were 
defined according to the Anticholinergic Risk Scale [31], 
and we also included B01AC07 (dipyridamole), R05DA04 
(codeine) and N02AX02 (tramadol) from the Anticholiner-
gic Drug Scale [32] as DAPs. Drug use was retrieved from 
medical records confirmed by spouses.
2.3  Interventions
A detailed description of the intervention has been previ-
ously published [22]. The health status of each patient start-
ing in the intervention groups was assessed by a geriatrician 
to ensure patient safety.
The home exercise group received a tailored exercise 
intervention at patients’ homes for two 1-h sessions weekly 
for 1 year. The intervention was administered by a physi-
otherapist and was individually tailored to improve everyday 
skills while taking into account patients’ needs. The group-
based exercise intervention group also trained for approxi-
mately 1 h twice weekly for 1 year. Adult daycare centre 
visits lasted for 4 h, of which the individual training time 
was approximately 1 h. Patients were transferred by taxis to 
daycare centres, and they also had lunch during the visits. 
The group consisted of 10 patients and two physiotherapists. 
Both groups performed aerobic, strength, balance, endur-
ance and multitasking training.
The control group received normal community care and 
was allowed to receive rehabilitation in the public healthcare 
system, including physiotherapy.
All patients and their spousal caregivers in both the inter-
vention and control groups received advice on nutrition and 
exercise. In addition, all patients were recommended to take 
vitamin D supplements (20 µg/day).
2.4  Statistical Analysis
The characteristics of the control and intervention groups are 
presented as means with standard deviations (SD), medians 
with interquartile ranges (IQRs), or as counts with percent-
ages. Statistical comparison between the groups was per-
formed by t test or bootstrap-type t-test; Chi square tests 
were performed when appropriate. Fall incidence rates (per 
person-year) with 95% confidence intervals (CIs) were cal-
culated assuming a Poisson distribution. Poisson regression 
models with count of falls events as the main outcome were 
used to model the relationship between exercise and medi-
cation. Models included age, sex, and the motor part of the 
FIM test (FIMmotor) value as covariates. The assumptions 
of overdispersion in the Poisson model were tested using the 
Lagrange multiplier test, and the normality of the variables 
was tested using the Shapiro–Wilk W test. The Stata 15.0 
statistical package (StataCorp LLC, College Station, TX, 
USA) was used for the analyses.
3  Results
Five patients died and 11 declined to participate immedi-
ately after randomization. Thus, a total of 194 patients were 
included in the analysis. The baseline characteristics are 
shown in Table 1 (the intervention and control groups); there 
were no significant differences in the baseline characteristics 
between these groups.
3.1  Incidence Rate Ratios of Falls Among Patients 
With or Without Various Fall‑Related Drugs, 
Between the Intervention and Control Groups
Figure 1 shows the IRRs of falls during the 1-year trial. 
The four panels in Fig. 1 show falls among patients with or 
without polypharmacy, antihypertensives, psychotropics, or 
DAPs. The IRRs and 95% CIs are crude figures, whereas the 
p-values for group, medication and interaction are adjusted 
for sex, age, and FIMmotor (motor part of the FIM test).
Among those without polypharmacy, the intervention 
group had 0.6 falls per person-year (95% CI 0.5–0.8) and the 
control group had 1.0 falls per person-year (95% CI 0.8–1.3). 
Among those with polypharmacy, (nine or more regular 
drugs), the intervention group had 1.0 falls per person-year 
(95% CI 0.8–1.3) and the control group had 1.9 falls per 
person-year (95% CI 1.4–2.4) [p < 0.001 for group, p = 0.23 
for medication, p = 0.17 for interaction, adjusted for sex, 
age, and FIMmotor].
Among those not taking antihypertensives, the intervention 
group had 1.2 falls per person-year (95% CI 1.0–1.4) and the 
control group had 0.9 falls per person-year (95% CI 0.6–1.2). 
Among those taking antihypertensives, the intervention group 
had 0.5 falls per person-year (95% CI 0.4–0.6) and the con-
trol group had 1.5 falls per person-year (95% CI 1.2–1.8) 
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[p < 0.001 for group, p  = 0.067 for medication, p < 0.001 for 
interaction, adjusted for sex, age, and FIMmotor].
Among those not taking psychotropics, the intervention 
group had 0.7 falls per person-year (95% CI 0.6–0.9) and the 
control group had 0.8 falls per person-year (95% CI 0.6–1.0). 
Among those taking psychotropics, the intervention group 
had 0.7 falls per person-year (95% CI 0.6–0.9) and the con-
trol group had 2.0 falls per person-year (95% CI 1.6–2.5) 
[p < 0.001 for group, p = 0.071 for medication, p  < 0.001 for 
interaction, adjusted for sex, age, and FIMmotor].
Among those not taking DAPs, the intervention group had 
0.6 falls per person-year (95% CI 0.5–0.7) and the control 
group had 1.2 falls per person-year (95% CI 1.0–1.4). Among 
those taking DAPs, the intervention group had 1.1 falls per 
person-year (95% CI 0.8–1.3) and the control group had 1.5 
falls per person-year (95% CI 1.0–2.1) [p < 0.001 for group, 
p = 0.014 for medication, p = 0.97 for interaction, adjusted for 
sex, age, and FIMmotor].
We performed additional analyses using age, sex, FIMmo-
tor, Charlson Comorbidity Index and CDR class as covari-
ates. These analyses did not change the main findings (data 
not shown).
4  Discussion
The exercise intervention significantly modified the risk 
for falls among patients using antihypertensive or psycho-
tropic medications; however, the risk associated with tak-
ing DAPs or polypharmacy was not modified by exercise 
intervention. This is the first study to explore how exer-
cise modifies the risk for falls caused by medications in 
patients with dementia.
A meta-analysis found exercise and multifactorial 
interventions to be most effective in reducing falls [33]. 
Other possible interventions for community-dwelling 
older persons include reducing the number of drugs, 
reducing psychoactive medications and modifying the 
home environment, as previously stated [1]. However, 
there are few studies that have investigated interventions 
to reduce falls among dementia patients. In 2015, two 
meta-analyses suggested that exercise has the potential to 
prevent falls among persons with known cognitive impair-
ment and dementia [19, 20]; however, there is insufficient 
knowledge on the specific mechanisms on why and how 
Table 1  Baseline characteristics in the control and intervention groups
a The difference between groups was tested by t test, bootstrap type t test, or Chi square test
SD standard deviation, BMI body mass index, MNA Mini-Nutritional Assessment [23], CDR Clinical Dementia Rating scale [25], FIM Func-
tional Independence Measure [27], SPPB Short Physical Performance Battery [28]
Control (N =65) Intervention (N =129) p  valuea
Male [n (%)] 39 (60) 80 (62) 0.79
Age, years [mean (SD)] 78 (5) 78 (5) 0.75
Education < 8 years [n (%)] 29 (45) 48 (37) 0.32
BMI [mean (SD)] 25.0 (3.9) 25.9 (3.4) 0.12
MNA [mean (SD)] 22 (2) 23 (2) 0.29
Blood pressure [mean (SD)]
 Systolic 150 (27) 150 (25) 0.97
 Diastolic 75 (12) 77 (12) 0.22
Charlson Comorbidity Index [24] [mean (SD)] 3.0 (1.7) 2.6 (1.8) 0.12
Number of drugs [mean (SD)] 6.6 (3.0) 6.5 (3.6) 0.94
CDR [n (%)] 0.72
 0.5–1 22 (34) 44 (34)
 2 34 (52) 61 (47)
 3 9 (14) 24 (19)
FIM [mean (SD)] 88 (18) 88 (19) 0.85
SPPB total [mean (SD)] 9.8 (2.0) 9.6 (2.3) 0.23
Vision problem [n (%)] 8 (12) 9 (7) 0.22
Fallen in previous year [n (%)] 32 (49) 48 (37) 0.11
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exercise may reduce falls and whether there are interac-
tions between risk and protective factors for falls. In this 
study, our purpose was to investigate possible interactions 
between exercise intervention and FRDs. The results from 
the present study add to the literature as we found exercise 
intervention to interact with antihypertensives and psy-
chotropics (Fig. 1). With respect to antihypertensives, the 
mechanism could be better circulation as exercise induces 
calf muscles to work better to enhance blood return to 
the heart and brain. In this way, exercise may decrease 
the risk related to some antihypertensives for orthostatic 
hypotension. For both medications, one explanation could 
be better balance and mobility as a result of exercise train-
ing. Although exercise intervention was associated with a 
reduced risk of falls among both DAP non-users and users, 
there was no interaction effect. A similar pattern was seen 
among those with and without polypharmacy.
While our findings indicate that these medications may 
increase the risk of falls among people with dementia, exer-
cise has the potential to completely compensate for this risk 
among users of antihypertensives and psychotropics. Thus, 
dementia patients with hypertension should be encouraged 
to exercise. Exercise should also be encouraged among peo-
ple with dementia taking psychotropics, although a reduction 
or deprescribing of psychotropics may be the primary aim to 
decrease the risk of falls. Exercise should also be encouraged 
among people with dementia with polypharmacy or taking 
DAPs. However, exercise does not completely compensate 
for their risk of falls, thus the primary aim for these patients 
should be to reduce polypharmacy and deprescribe DAPs.
The FINALEX study (a randomized controlled trial) 
has several strengths. Every participant had a confirmed 
diagnosis of AD. The intervention was highly coordinated 
and a physiotherapist supervised each training session. The 
intervention was also frequent (twice weekly) and long term 
(12 months). The intervention (implemented by physiother-
apists in primary care) did not increase the total costs of 
social and health services [21]. Fall diaries kept by spouses 
served to assess the falls (a diary is a highly sensitive method 
to accurately record falls) [34]. The medications used were 
confirmed from both medical records and spousal caregiv-
ers. There were no significant differences in the baseline 
characteristics between the intervention and control groups. 
In addition, the baseline characteristics presented similar 
features as seen in previous studies among dementia patients 
[12], giving reliability to the results in this patient group.
This study also has several limitations. All participants 
were community-dwelling Caucasians living in their 
homes with their spousal caregivers. Generalising these 
results to other populations should be undertaken with 
caution. An ideal design to test our hypothesis would be 
randomizing AD patients taking psychotropics or anti-
hypertensives into two groups and testing exercise inter-
vention among these groups; however, recruitment into 
this kind of trial might be challenging. This is a subgroup 
analysis of the original randomised trial and we combined 
the original two intervention groups. The small sample 
size decreased the power of the study and the study was 
Fig. 1  Falls in participants with or without. a Polypharmacy, b anti-
hypertensives, c psychotropics, and d DAPs. Values shown are 
incidence rate ratios ± 95% confidence intervals. DAPs drugs with 
anticholinergic properties
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not blinded; however, the study nurses collecting the data 
were uninformed about the exact intervention and primary 
outcome measures and were not researchers in the study. 
Moreover, the spousal caregivers’ evaluations were used 
to assess the FIM scores [27] and falls of the patients. 
Spouses were also not aware of the study hypothesis. The 
differences between the original intervention and control 
groups were probably decreased because patients in the 
control group received high-quality community care and 
were also allowed to receive physiotherapy. Although 
medications used at the end of the study were not con-
firmed, this study intervention did not intend to change 
them.
5  Conclusions
The exercise intervention in the FINALEX study has the 
potential to modify the risk of falls among people with 
dementia taking antihypertensives and psychotropics. 
Exercise is beneficial to all people with dementia; how-
ever, primary care should pay particular attention to peo-
ple with dementia taking antihypertensives or psychotrop-
ics for medical conditions, and motivate them to exercise 
to reduce their risk of falls.
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